February 03, 2013 at 23:30 PM EST
Prima BioMed Announces Two Accepted Abstracts for Presentation at ISCT Annual Meeting

SYDNEY, AUSTRALIA -- (Marketwire) -- 02/03/13 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company") announces that two abstracts related to research and development of CVac™ have been accepted by the International Society for Cellular Therapy (ISCT) for presentation at its 19th annual meeting in Auckland, New Zealand from 22-25 April 2013.

The two poster presentations are;

  • "Qualification of an intracellular cytokine staining (ICS) assay to evaluate mucin 1-specific T cell responses in ovarian cancer patients treated with CVac™ immunotherapy" by Dr. Sharron Gargosky et al.; and
  • "Qualification of the COSTIM assay to determine potency and use in clinical trials" by Dr. Michael Buchholtz et al.

Dr. Gargosky's poster will describe the use of intracellular cytokine staining (ICS) assays to measure mucin 1-specific T cells in patient's peripheral blood mononuclear cells (PBMC). Dr. Buchholtz's poster will describe the process of developing and qualifying the COSTIM assay to assess the potency of a product like CVac™.

Both posters will be presented during the Immunotherapy, Regenerative Medicine, Translational Process Development and Gene Therapy session on Wednesday, 24 April 2013 from 5:00pm to 6:30pm.

About Prima BioMed
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.

For further information please contact:

USA Investor/Media:
Ms. Jessica Brown
Prima BioMed Ltd.
+1 (919) 710-9061
Email Contact

Australia Investor/Media:
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Email Contact

Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Email Contact

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here